BioLineRx (BLRX) Cash from Operations Growth (5y) (2018 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.04% |
| Sep 30, 2025 | 17.38% |
| Jun 30, 2025 | 49.82% |
| Mar 31, 2025 | 17.40% |
| Dec 31, 2024 | -9.66% |
| Sep 30, 2024 | -9.75% |
| Jun 30, 2024 | -11.94% |
| Mar 31, 2024 | -25.01% |
| Dec 31, 2023 | 24.33% |
| Sep 30, 2023 | -10.50% |
| Jun 30, 2023 | -9.21% |
| Mar 31, 2023 | -3.32% |
| Dec 31, 2022 | 2.11% |
| Sep 30, 2022 | -6.91% |
| Jun 30, 2022 | -8.34% |
| Mar 31, 2022 | -8.05% |
| Dec 31, 2021 | -6.14% |
| Sep 30, 2021 | -10.95% |
| Jun 30, 2021 | -15.92% |
| Mar 31, 2021 | -8.28% |
| Dec 31, 2020 | -11.25% |
| Sep 30, 2020 | -7.36% |
| Jun 30, 2020 | -8.64% |
| Mar 31, 2020 | -14.21% |
| Dec 31, 2019 | -2.61% |
| Sep 30, 2019 | -13.72% |
| Jun 30, 2019 | -8.22% |
| Mar 31, 2019 | -6.39% |
| Dec 31, 2018 | -6.70% |
| Sep 30, 2018 | -6.80% |
| Jun 30, 2018 | -0.04% |
| Mar 31, 2018 | -5.29% |